MedPath

altrexone as anti-craving medication in cannabis addicts

Phase 3
Withdrawn
Conditions
verslaving aan cannabis
cannabis addiction
Registration Number
NL-OMON35633
Lead Sponsor
Centrum Maliebaan (Utrecht)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

male or female
between 18 - 60 years old
current primary diagnosis of cannabis abuse or dependence
able to provide written informed consent and to comply with all study procedures

Exclusion Criteria

currently dependent on opiates
currently majorly dependant on another substance other than cannabis or nicotine
severe medical illness
known allergy to Naltrexone

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath